CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 285 enrolled
Drug / intervention
InterStim Sacral Nerve Stimulation Therapydevice
Likely dose
InterStim Sacral Nerve Stimulation Therapy (device implant)AI-extracted
Key inclusion· 4
  • Diagnosed with chronic fecal incontinence lasting >6 months (>12 months post-vaginal childbirth), defined as >2 incontinent episodes per week on average (more than staining) during baseline diary period
  • Failed or are not suitable candidates for conservative treatments
  • Age 18 years or older
  • Willing and able to complete bowel diaries and questionnaires throughout the study
Key exclusion· 15
  • Congenital anorectal malformations
  • Active rectal prolapse
  • Prior rectal surgery (rectopexy, resection) or sphincteroplasty within 12 months (24 months for cancer)
  • Neurological diseases including clinically significant peripheral neuropathy or complete spinal cord injury

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00200057
NCT00200057N/ACompleted

Medtronic InterStim® Sacral Nerve Stimulation Therapy for Bowel Control: Fecal Incontinence Study

MedtronicNeuro·interventional·Posted Sep 20, 2005·Updated Jan 24, 2013

In Brief

A clinical study evaluating InterStim Sacral Nerve Stimulation Therapy for Fecal Incontinence. Completed, enrolled 285 participants across 13 sites in 2 countries.

Detailed Summary

Fecal incontinence (FI) is a difficulty in storing gas, liquid stool or solid stool (bowel movement) in order to expel it at a proper time and place. Patients who suffer from FI may experience passive FI (difficulty in sensing stool in the rectum) or urgency (able to sense a bowel movement but cannot hold the stool until an acceptable time and place). FI is not a life-threatening disease, but it is often profoundly distressing and socially incapacitating. If a patient is suffering with symptoms of chronic FI despite trying oral medications, biofeedback and/or other more conservative treatments, a patient may be eligible to participate in a clinical research study to evaluate the safety and effectiveness of sacral nerve stimulation for the treatment of chronic fecal incontinence. One hundred-twenty (120) patients will be implanted with medical devices and followed closely for twelve months, and then once a year after that until the study closes. There are up to 20 centers in the United States.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--

Timeline

N/ACompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartJan 1, 2002
Primary CompletionAug 1, 2007
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 20.8 years ago

Interventions

InterStim Sacral Nerve Stimulation Therapydevice

Open label study. All subjects that qualify for the study will be implanted.